Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPA 4 g/day Clear all

Conditions: Severe Hypertriglyceridemia
Interventions: Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Age-related Memory Disorders, Mood Disorders
Interventions: Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder; Dietary Supplement · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 62 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Elevated Triglycerides, Cardiovascular Risk Factor
Interventions: DPA enriched n-3, n-3 control, Placebo; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Colon Cancer
Interventions: AMR101 (VASCEPA, icosapent ethyl); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nutrition, Healthy
Interventions: DHA/EPA fortified chicken plus Placebo, non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement, non-DHA bio-enhanced chicken plus supplement DHA Omega-3, 25(OH)D bioenhanced chicken and eggs plus placebo, Dietary Supplement: DHA/EPA fortified eggs plus Placebo, non-DHA bio-enhanced eggs plus supplement DHA Omega-3, non-25(OH)D fortified chicken/eggs plus placebo; Dietary Supplement · Other
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Hypertriglyceridemia
Interventions: Omega-3-acid ethyl esters, Placebo; Drug
Lead sponsor: Babu Balagopal; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid; Drug · Dietary Supplement
Lead sponsor: Carsten Skarke, MD; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertriglyceridemia
Interventions: DHA-enriched, EPA-enriched; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 20 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: EPA enriched fish oils; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mather, California

Conditions: Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions: Eicosapentaenoic acid (omega-3 fatty acid), Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Hypertriglyceridemia
Interventions: rosuvastatin 40 mg tablet, Epanova™ QD (2 x 1 g capsules), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose, Multiple (20) oral doses of 2 g Vascepa® every 12 hours; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Type 2 Diabetes, Coronary Artery Disease
Interventions: Icosapent ethyl; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment Resistant Depression, Inflammation, Overweight
Interventions: Omega 3, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah

Conditions: Chronic Obstructive Pulmonary Disease, Muscle Wasting
Interventions: Olive oil, Fish oil, Fish oil and placebo; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Alzheimer's Disease
Interventions: icosapent ethyl (IPE), gel cap placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions: Fish Oil, Flaxseed Oil, Placebo; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Hypertriglyceridemia
Interventions: Simvastatin, acetylsalicylic acid (ASA), omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Major Depressive Disorder, Overweight, Inflammation
Interventions: Placebo, EPA 1 g/day, EPA 2 g/day, EPA 4 g/day; Other · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Hypertriglyceridemia
Interventions: 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks; Drug
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: University Park, Pennsylvania

Search by objective public record fields.

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer

Bioavailability of Vitamin D(25(OH)D) and Omega-3 Fatty Acid (DHA) Enhanced Chicken

Fish Oil Study for High Triglyceride Levels in Children

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

Supplementation With Omega-3: Mechanism of Action

Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)

Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

Effects of Omega-3 Fatty Acids on Markers of Inflammation

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides